Evidence map›Paper›PMID 32206951›Full record

ArticleAnnals of surgical oncology2020

Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients.

Miwa Noda, Takaaki Masuda, Shuhei Ito, Taro Tobo, Akihiro Kitagawa, Qingjiang Hu, Dai Shimizu, Hidetoshi Eguchi, Tsuyoshi Etoh, Shinji Ohno and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Miwa NodaDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
Takaaki MasudaDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
Shuhei ItoDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
Taro ToboDepartment of Clinical Laboratory Medicine, Kyushu University Beppu Hospital, Beppu, Japan.
Akihiro KitagawaDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
Qingjiang HuDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
Dai ShimizuDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
Hidetoshi EguchiDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Japan.
Tsuyoshi EtohDepartment of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Yufu, Japan.
Shinji OhnoBreast Oncology Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Masafumi InomataDepartment of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Yufu, Japan.
Koshi MimoriDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Japan. kmimori@beppu.kyushu-u.ac.jp.

Funding

Grant-in-Aid for Scientific Research on Innovative Areas 15H0912Japan Society for the Promotion of Science Grant-in-Aid for Science Research JP16K07177Japan Society for the Promotion of Science Grant-in-Aid for Science Research JP16K10543Japan Society for the Promotion of Science Grant-in-Aid for Science Research JP17K10593Japan Society for the Promotion of Science Grant-in-Aid for Science Research JP17K16454Japan Society for the Promotion of Science Grant-in-Aid for Science Research JP17K16521Japan Society for the Promotion of Science Grant-in-Aid for Science Research JP17K19608JSPS KAKENHI 15H05707Priority Issue on Post-K computer hp160219Priority Issue on Post-K computer hp170227
6 · The paper itself

Abstract

backgroundProgrammed cell death 1 (PD-1) inhibitors have shown significant therapeutic promise in various cancers. However, the clinical significance of PD-1 expression remains not fully understood. In this study, we evaluated the clinical and prognostic relevance of PD-1 expression in breast cancer (BC).

methodsFirst, we analyzed PD-1 mRNA expression in BC tissues and performed a survival analysis using a dataset from The Cancer Genome Atlas. Next, we measured PD-1 mRNA expression in peripheral blood (PB) in BC patients by quantitative reverse-transcription polymerase chain reaction. We performed a survival analysis and evaluated the association between PD-1 mRNA expression in PB and the clinicopathological features of 372 BC patients who underwent curative resection. Flow cytometry (FCM) analysis was performed to identify PD-1-expressing cells in PB. Finally, we determined whether there was a correlation of PD-1 mRNA expression in PB and tumor tissue.

resultsPD-1 mRNA expression was significantly higher in tumor tissues compared with normal tissues. Decreased PD-1 mRNA expression in tumor tissue was associated with poor overall survival (OS). PD-1 mRNA expression in PB of BC patients was higher than that of healthy volunteers, and increased PD-1 mRNA expression in PB was associated with poor OS. FCM revealed that PD-1 was mostly expressed on T cells in PB, predominantly in CD4

conclusionHigh expression of PD-1 mRNA in preoperative PB could serve as an effective biomarker that indicates poor prognosis in BC.

Indexed as

Breast NeoplasmsBiomarkers, TumorHumansPrognosisProgrammed Cell Death 1 ReceptorRNA, MessengerBiomarkers, TumorPDCD1 protein, humanProgrammed Cell Death 1 ReceptorRNA, Messenger

Identifiers

PMID32206951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.